Project/Area Number |
18K07970
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Review Section |
Basic Section 53010:Gastroenterology-related
|
Research Institution | Osaka University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
水島 恒和 大阪大学, 医学系研究科, 寄附講座教授 (00527707)
|
Project Period (FY) |
2018-04-01 – 2021-03-31
|
Project Status |
Completed (Fiscal Year 2020)
|
Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2019: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2018: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
Keywords | 大腸癌 / 免疫治療 / マイクロRNA / がん遺伝子 / 癌 |
Outline of Final Research Achievements |
Immune escape is a key feature of cancer survival and progression. In our study, we aimed to identify microRNAs that plays a key role in inhibiting the tumor immunity and contribute to cancer progression. We successfully discovered microRNAs and genes that strongly overexpressed in cancer stromal tissues and confirmed that these molecules functions as crucial inhibitors of tumor immune system. Combinational use of inhibitors to these molecules and conventional immunotherapy could be a promising treatment strategy in colorectal cancer.
|
Academic Significance and Societal Importance of the Research Achievements |
本研究では、腫瘍免疫に重要な役割を果たすマイクロRNAの同定と、その機能の解析を行った。大腸癌細胞株の実験と大規模オープンデータベースの解析から、間質においてがん免疫を抑制し、癌進展に関わるマイクロRNA、ならびに遺伝子候補群の同定に成功、これらが癌組織で高発現していることを確認した。現行の免疫チェックポイント阻害剤をはじめとする免疫治療に加えて、今回同定した分子を抑制することは、今後の大腸癌治療戦略において、重要な選択肢となり得る。
|